Over the past year there were no insider purchases at Pyxis Oncology, Inc.. Two insiders sold roughly $123,000 instead.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Big money check: 76 institutions held PYXS as of Q2 2026, and funds were split between buying and selling. Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Dupont Jakob | Director | Sell | 35,000 | $3.06 | $107K | SEC |
| Mar 25, 2026 | HUMPHREY RACHEL | Director | Sell | 1,400 | $0.97 | $1K | SEC |
| Mar 25, 2026 | HUMPHREY RACHEL | Director | Sell | 13,896 | $1.03 | $14K | SEC |
| Mar 25, 2026 | HUMPHREY RACHEL | Director | Sell | 200 | $0.97 | $194 | SEC |
| Nov 27, 2024 | Connealy Pamela Ann | CFO | Buy | 5,450 | $2.00 | $11K | SEC |
| Nov 27, 2024 | Connealy Pamela Ann | CFO | Buy | 83,400 | $1.96 | $163K | SEC |
| Sep 28, 2023 | Connealy Pamela Ann | CFO | Buy | 8,000 | $1.87 | $15K | SEC |
| Sep 27, 2023 | Wadhane Jitendra | Executive Officer | Buy | 2,500 | $1.87 | $5K | SEC |
| Sep 27, 2023 | Connealy Pamela Ann | CFO | Buy | 6,426 | $1.85 | $12K | SEC |
| Sep 25, 2023 | Wadhane Jitendra | Executive Officer | Buy | 5,000 | $1.77 | $9K | SEC |
| Sep 25, 2023 | Connealy Pamela Ann | CFO | Buy | 12,000 | $1.67 | $20K | SEC |
| Sep 22, 2023 | Wadhane Jitendra | Executive Officer | Buy | 2,500 | $1.74 | $4K | SEC |
| Sep 22, 2023 | Connealy Pamela Ann | CFO | Buy | 5,000 | $1.74 | $9K | SEC |
| Sep 18, 2023 | Sullivan Lara | CEO | Sell | 100 | $2.25 | $225 | SEC |
| Sep 18, 2023 | Sullivan Lara | CEO | Sell | 8,541 | $2.10 | $18K | SEC |
In the last 12 months Pyxis Oncology, Inc. insiders made open-market purchases worth about $0 and sales worth about $123,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in PYXS was filed on 2026-07-02.
76 investment managers reported holding PYXS in SEC Form 13F filings for Q2 2026.
No congressional trades in PYXS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).